Bots, editor, reviewer, Administrators
13,941
edits
Feed:All articles/Pretty: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 7,393: | Line 7,393: | ||
"title" : "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy", | "title" : "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy", | ||
"pmid" : "23877348" | "pmid" : "23877348" | ||
}, | |||
{ | |||
"timestamp" : "2022-03-10T21:09:46Z", | |||
"briefDesignDescription" : "Rituximab in ANCA-Renal Vasculitis", | |||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/nejmoa0909169", | |||
"pageid" : 4459, | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa0909169", | |||
"trainingLevel" : "fellow", | |||
"citation" : "Jones RB, <i>et al</i>. \"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis\". <i>The New England Journal of Medicine</i>. 2010. 363(3):211-232.", | |||
"subspecialties" : "Rheumatology;Nephrology", | |||
"expansion" : "", | |||
"statusUsableDate" : "2022-03-10", | |||
"briefResultsDescription" : "Rituximab not superior to cyclophosphamide", | |||
"published" : "2010-07-15", | |||
"pageName" : "RITUXVAS", | |||
"diseases" : "Vasculitis;ANCA-Associated Vasculitis;Renal Vasculitis", | |||
"abbreviation" : "RITUXVAS", | |||
"title" : "Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis", | |||
"pmid" : "20647198" | |||
}, | }, | ||
{ | { | ||